US equities |
MU $1,068.49 ▼-1.79% NVDA $236.62 ▼-0.36% PLTR $200.25 ▲+3.16% SNDK $1,648.46 ▼-2.60% AMD $637.19 ▼-1.34% META $723.01 ▲+0.24% INTC $109.65 ▼-3.07% TSLA $373.20 ▼-1.22%
FinancialContent

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

3.370 -0.090 (-2.60%)
Delayed Quote Updated: 10:11 AM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
32 33 Next >
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential to Represent Multiple Commercial Opportunities
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Novel DehydraTECH(TM) Technology to Address Unmet Antihypertension Drug Market
Via Investor Brand Network
Flora Growth Corp. (NASDAQ: FLGC) Building Portfolio of Brands that Resonates with End Consumers as It Targets Margins and Profitability
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program Seeking to Provide Safe, Well-Tolerated, Effective Antihypertensive Medication Amid Continued Reports of Suboptimal Adherence to Existing Treatments
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Pipeline Addressing Severe Unmet Patient Needs
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Pipeline Addressing Severe Unmet Patient Needs
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Patented DehydraTECH(TM) Technology to Fight America’s Silent Killer – Hypertension
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Offering Solutions to Growing Hypertension Problem Worldwide
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Address Declining Antihypertensive Intensification and High Prescription Abandonment Rates, with DehydraTECH-CBD
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Redefining Drug Delivery Platforms
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Focusing on Multiple Mainstream Applications of Its Disruptive Patented DehydraTECH(TM) Technology
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Expand Indications, Efficacy of DehydraTECH(TM)
Via Investor Brand Network
Topics Cannabis Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Expand Indications, Efficacy of DehydraTECH(TM)
Via CannabisNewsWire
Topics Cannabis Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Addressing Hypertensive Patients’ Concerns with DehydraTECH-CBD
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Provide Bioavailable Oral Treatment for Hypertension, Mitigate Effects of High Blood Pressure
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Hypertension Drug Market with Proprietary Drug-Delivery Method
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Hypertension Drug Market with Proprietary Drug-Delivery Method
Via Investor Brand Network
Topics Intellectual Property
News headline image
Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields Remarkable Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Lexaria Bioscience Corp. (NASDAQ: LEXX), Growing its Market Share, One Patent at a Time
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Strengthens Board of Directors to Boost Efforts toward Regulatory Approval of Potential Treatment for Hypertension
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Acquires 27th Worldwide Patent Applying to a Range of APIs in Ready-to-Drink Consumer Retail Beverage Products
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Quest to Find Hypertension Treatment Promising With DehydraTECH(TM)’s Ability to Boost Bioavailability
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Patent in Mexico
Via Investor Brand Network
Topics Cannabis Intellectual Property
News headline image
Lexaria Receives New Patent in Mexico
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces the Availability of a Broadcast titled, “The Power of Science to Stop a Killer”
Via Investor Brand Network
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
32 33 Next >